New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family

Molecular Oncology

Volumn 1, Issue 3, 2007, Pages 269-287

  Emami, Nashmil ^a,b   Diamandis, Eleftherios P ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Angiogenesis; Kallikrein related peptidases; PARs; Proteolytic cascades; PSA; Semen liquefaction; Skin desquamation; Tumour growth; Tumour invasion; uPA signaling

Indexed keywords

BIOLOGICAL MARKER; KALLIKREIN; PEPTIDASE; PLASMINOGEN ACTIVATOR INHIBITOR 3; SERINE PROTEINASE;

BODY FLUID; CANCER; CANCER CLASSIFICATION; CANCER INVASION; CLINICAL STUDY; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME SPECIFICITY; GENE CLUSTER; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENETIC CONSERVATION; GENETIC ORGANIZATION; GENETIC TRANSCRIPTION; HOMEOSTASIS; HORMONE DEPENDENCE; HUMAN; LIQUEFACTION; NERVE CELL PLASTICITY; PHYLOGENY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; REVIEW; SEMEN ANALYSIS; SIGNAL TRANSDUCTION; SKIN EXFOLIATION;

EID: 36549048804     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2007.09.003     Document Type: Review

References (185)

1. Amour A., Bird M., Chaudry L., Deadman J., Hayes D., and Kay C. General considerations for proteolytic cascades. Biochem. Soc. Trans. 32 (2004) 15-16
2. Angelo P.F., Lima A.R., Alves F.M., Blaber S.I., Scarisbrick I.A., Blaber M., Juliano L., and Juliano M.A. Substrate specificity of human kallikrein 6: salt and glycosaminoglycan activation effects. J. Biol. Chem. 281 (2006) 3116-3126
3. Bakin R.E., Gioeli D., Sikes R.A., Bissonette E.A., and Weber M.J. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res. 63 (2003) 1981-1989
4. Bando Y., Ito S., Nagai Y., Terayama R., Kishibe M., Jiang Y.P., Mitrovic B., Takahashi T., and Yoshida S. Implications of protease M/neurosin in myelination during experimental demyelination and remyelination. Neurosci. Lett. 405 (2006) 175-180
5. Barrett A.J., Rawlings N.D., and Woessner J.F. Handbook of Proteolytic Enzymes (2004), Academic Press Inc, San Diego
6. Bayes A., Tsetsenis T., Ventura S., Vendrell J., Aviles F.X., and Sotiropoulou G. Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation. Biol. Chem. 385 (2004) 517-524
7. Beato M. Gene regulation by steroid hormones. Cell 56 (1989) 335-344
8. Beaufort N., Debela M., Creutzburg S., Kellermann J., Bode W., Schmitt M., Pidard D., and Magdolen V. Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR). Biol. Chem. 387 (2006) 217-222
9. Bernett M.J., Blaber S.I., Scarisbrick I.A., Dhanarajan P., Thompson S.M., and Blaber M. Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J. Biol. Chem. 277 (2002) 24562-24570
10. Bindukumar B., Schwartz S.A., Nair M.P., Aalinkeel R., Kawinski E., and Chadha K.C. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia 7 (2005) 241-252
11. Biyashev D., Tan F., Chen Z., Zhang K., Deddish P.A., Erdos E.G., and Hecquet C. Kallikrein activates bradykinin B2 receptors in absence of kininogen. Am. J. Physiol Heart Circ. Physiol 290 (2006) H1244-H1250
12. Borg T.K. It's the matrix! ECM, proteases, and cancer. Am. J. Pathol. 164 (2004) 1141-1142
13. Borgono C.A., and Diamandis E.P. The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 4 (2004) 876-890
14. Borgono C.A., Grass L., Soosaipillai A., Yousef G.M., Petraki C.D., Howarth D.H., Fracchioli S., Katsaros D., and Diamandis E.P. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res. 63 (2003) 9032-9041
15. Borgono C.A., Michael I.P., and Diamandis E.P. Human tissue kallikreins: physiologic roles and applications in cancer. Mol. Cancer Res. 2 (2004) 257-280
16. Borgono C.A., Michael I.P., Komatsu N., Jayakumar A., Kapadia R., Clayman G.L., Sotiropoulou G., and Diamandis E.P. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J. Biol. Chem. 282 (2006) 3640-3652
17. Borgono C.A., Michael I.P., Shaw J.L., Luo L.Y., Ghosh M.C., Soosaipillai A., Grass L., Katsaros D., and Diamandis E.P. Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. J. Biol. Chem. (2006)
18. Brattsand M., and Egelrud T. Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. J. Biol. Chem. 274 (1999) 30033-30040
19. Brattsand M., Stefansson K., Lundh C., Haasum Y., and Egelrud T. A proteolytic cascade of kallikreins in the stratum corneum. J. Invest. Dermatol. 124 (2005) 198-203
20. Campbell D.J. The kallikrein-kinin system in humans. Clin. Exp. Pharmacol. Physiol. 28 (2001) 1060-1065
21. Caubet C., Jonca N., Brattsand M., Guerrin M., Bernard D., Schmidt R., Egelrud T., Simon M., and Serre G. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J. Invest. Dermatol. 122 (2004) 1235-1244
22. Chao J., and Chao L. Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp. Physiol. 90 (2005) 291-298
23. Chao J., Bledsoe G., Yin H., and Chao L. The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. Biol. Chem. 387 (2006) 665-675
24. Chavanas S., Bodemer C., Rochat A., Hamel-Teillac D., Ali M., Irvine A.D., Bonafe J.L., Wilkinson J., Taieb A., Barrandon Y., Harper J.I., de Prost Y., and Hovnanian A. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat. Genet. 25 (2000) 141-142
25. Chen V.C., Chao L., and Chao J. Reactive-site specificity of human kallistatin toward tissue kallikrein probed by site-directed mutagenesis. Biochim. Biophys. Acta 1479 (2000) 237-246
26. Chen V.C., Chao L., and Chao J. Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein. J. Biol. Chem. 275 (2000) 38457-38466
27. Chowdhury I., Tharakan B., and Bhat G.K. Current concepts in apoptosis: the physiological suicide program revisited. Cell Mol. Biol. Lett. 11 (2006) 506-525
28. Christofori G. New signals from the invasive front. Nature 441 (2006) 444-450
29. Cinar B., Yeung F., Konaka H., Mayo M.W., Freeman M.R., Zhau H.E., and Chung L.W. Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells. Biochem. J. 379 (2004) 421-431
30. Cleutjens K.B., van Eekelen C.C., van der Korput H.A., Brinkmann A.O., and Trapman J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J. Biol. Chem. 271 (1996) 6379-6388
31. Cleutjens K.B., van der Korput H.A., van Eekelen C.C., van Rooij H.C., Faber P.W., and Trapman J. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol. Endocrinol. 11 (1997) 148-161
32. Cloutier S.M., Chagas J.R., Mach J.P., Gygi C.M., Leisinger H.J., and Deperthes D. Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology. Eur. J. Biochem. 269 (2002) 2747-2754
33. Colman R.W. Regulation of angiogenesis by the kallikrein-kinin system. Curr. Pharm. Des 12 (2006) 2599-2607
34. Davidson B., Xi Z., and Saatcioglu F. Kallikrein 4 is expressed in malignant mesothelioma-further evidence for the histogenetic link between mesothelial and epithelial cells. Diagn. Cytopathol. 35 (2007) 80-84
35. Debela M., Magdolen V., Grimminger V., Sommerhoff C., Messerschmidt A., Huber R., Friedrich R., Bode W., and Goettig P. Crystal structures of human tissue kallikrein 4: activity modulation by a specific zinc binding site. J. Mol. Biol. 362 (2006) 1094-1107
36. Debela M., Magdolen V., Schechter N., Valachova M., Lottspeich F., Craik C.S., Choe Y., Bode W., and Goettig P. Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. J. Biol. Chem. 281 (2006) 25678-25688
37. Denmeade S.R., Lovgren J., Khan S.R., Lilja H., and Isaacs J.T. Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing. Prostate 48 (2001) 122-126
38. Denmeade S.R., Litvinov I., Sokoll L.J., Lilja H., and Isaacs J.T. Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo. Prostate 56 (2003) 45-53
39. Deperthes D. Phage display substrate: a blind method for determining protease specificity. Biol. Chem. 383 (2002) 1107-1112
40. Dery O., Corvera C.U., Steinhoff M., and Bunnett N.W. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am. J. Physiol 274 (1998) C1429-C1452
41. Descargues P., Deraison C., Bonnart C., Kreft M., Kishibe M., Ishida-Yamamoto A., Elias P., Barrandon Y., Zambruno G., Sonnenberg A., and Hovnanian A. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat. Genet. 37 (2005) 56-65
42. Descargues P., Deraison C., Prost C., Fraitag S., Mazereeuw-Hautier J., D'Alessio M., Ishida-Yamamoto A., Bodemer C., Zambruno G., and Hovnanian A. Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome. J. Invest. Dermatol. 126 (2006) 1622-1632
43. Desrivieres S., Lu H., Peyri N., Soria C., Legrand Y., and Menashi S. Activation of the 92 kDa type IV collagenase by tissue kallikrein. J. Cell Physiol. 157 (1993) 587-593
44. Diamandis E.P., Scorilas A., Fracchioli S., Van Gramberen M., De Bruijn H., Henrik A., Soosaipillai A., Grass L., Yousef G.M., Stenman U.H., Massobrio M., Van Der Zee A.G., Vergote I., and Katsaros D. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J. Clin. Oncol. 21 (2003) 1035-1043
45. Diamandis E.P., Scorilas A., Kishi T., Blennow K., Luo L.Y., Soosaipillai A., Rademaker A.W., and Sjogren M. Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. Clin. Biochem. 37 (2004) 230-237
46. Egelrud T., Brattsand M., Kreutzmann P., Walden M., Vitzithum K., Marx U.C., Forssmann W.G., and Magert H.J. hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6. Br. J. Dermatol. 153 (2005) 1200-1203
47. Ekholm E., and Egelrud T. Stratum corneum chymotryptic enzyme in psoriasis. Arch. Dermatol. Res. 291 (1999) 195-200
48. Elliott M.B., Irwin D.M., and Diamandis E.P. In silico identification and Bayesian phylogenetic analysis of multiple new mammalian kallikrein gene families. Genomics 88 (2006) 591-599
49. Emami N., and Diamandis E.P. Human tissue kallikreins: a road under construction. Clin. Chim. Acta 381 (2007) 78-84
50. Emanueli C., Minasi A., Zacheo A., Chao J., Chao L., Salis M.B., Straino S., Tozzi M.G., Smith R., Gaspa L., Bianchini G., Stillo F., Capogrossi M.C., and Madeddu P. Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 103 (2001) 125-132
51. Espana F., Fink E., Sanchez-Cuenca J., Gilabert J., Estelles A., and Witzgall K. Complexes of tissue kallikrein with protein C inhibitor in human semen and urine. Eur. J. Biochem. 234 (1995) 641-649
52. Felber L.M., Kundig C., Borgono C.A., Chagas J.R., Tasinato A., Jichlinski P., Gygi C.M., Leisinger H.J., Diamandis E.P., Deperthes D., and Cloutier S.M. Mutant recombinant serpins as highly specific inhibitors of human kallikrein 14. FEBS J. 273 (2006) 2505-2514
53. Fernando S.C., Najar F.Z., Guo X., Zhou L., Fu Y., Geisert R.D., Roe B.A., and Desilva U. Porcine kallikrein gene family: genomic structure, mapping, and differential expression analysis. Genomics 89 3 (2007) 429-438
54. Fidler I.J. Angiogenesis and cancer metastasis. Cancer J. 6 Suppl. 2 (2000) S134-S141
55. Fortier A.H., Nelson B.J., Grella D.K., and Holaday J.W. Antiangiogenic activity of prostate-specific antigen. J. Natl. Cancer Inst. 91 (1999) 1635-1640
56. Fortier A.H., Holaday J.W., Liang H., Dey C., Grella D.K., Holland-Linn J., Vu H., Plum S.M., and Nelson B.J. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. Prostate 56 (2003) 212-219
57. Foussias G., Yousef G.M., and Diamandis E.P. Identification and molecular characterization of a novel member of the siglec family (SIGLEC9). Genomics 67 (2000) 171-178
58. Frenette G., Tremblay R.R., Lazure C., and Dube J.Y. Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int. J. Cancer 71 (1997) 897-899
59. Giusti B., Serrati S., Margheri F., Papucci L., Rossi L., Poggi F., Magi A., Del Rosso A., Cinelli M., Guiducci S., Kahaleh B., Matucci-Cerinic M., Abbate R., Fibbi G., and Del Rosso M. The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis Rheum. 52 (2005) 3618-3628
60. Gomis-Ruth F.X., Bayes A., Sotiropoulou G., Pampalakis G., Tsetsenis T., Villegas V., Aviles F.X., and Coll M. The structure of human prokallikrein 6 reveals a novel activation mechanism for the kallikrein family. J. Biol. Chem. 277 (2002) 27273-27281
61. Goya M., Ishii G., Miyamoto S., Hasebe T., Nagai K., Yonou H., Hatano T., Ogawa Y., and Ochiai A. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer. Prostate 66 (2006) 1573-1584
62. Goyal J., Smith K.M., Cowan J.M., Wazer D.E., Lee S.W., and Band V. The role for NES1 serine protease as a novel tumor suppressor. Cancer Res. 58 (1998) 4782-4786
63. Hachem J.P., Wagberg F., Schmuth M., Crumrine D., Lissens W., Jayakumar A., Houben E., Mauro T.M., Leonardsson G., Brattsand M., Egelrud T., Roseeuw D., Clayman G.L., Feingold K.R., Williams M.L., and Elias P.M. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J. Invest. Dermatol. 126 (2006) 1609-1621
64. Hansson L., Backman A., Ny A., Edlund M., Ekholm E., Ekstrand H.B., Tornell J., Wallbrandt P., Wennbo H., and Egelrud T. Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: a model for chronic itchy dermatitis. J. Invest. Dermatol. 118 (2002) 444-449
65. Hansson L., Stromqvist M., Backman A., Wallbrandt P., Carlstein A., and Egelrud T. Cloning, expression, and characterization of stratum corneum chymotryptic enzyme. A skin-specific human serine proteinase. J. Biol. Chem. 269 (1994) 19420-19426
66. Harris J.L., Backes B.J., Leonetti F., Mahrus S., Ellman J.A., and Craik C.S. Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc. Natl. Acad. Sci. USA 97 (2000) 7754-7759
67. Hart P.S., Wright J.T., Savage M., Kang G., Bensen J.T., Gorry M.C., and Hart T.C. Exclusion of candidate genes in two families with autosomal dominant hypocalcified amelogenesis imperfecta. Eur. J. Oral Sci. 111 (2003) 326-331
68. Hart P.S., Hart T.C., Michalec M.D., Ryu O.H., Simmons D., Hong S., and Wright J.T. Mutation in kallikrein 4 causes autosomal recessive hypomaturation amelogenesis imperfecta. J. Med. Genet. 41 (2004) 545-549
69. Heidtmann H.H., Nettelbeck D.M., Mingels A., Jager R., Welker H.G., and Kontermann R.E. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br. J. Cancer 81 (1999) 1269-1273
70. Ishida-Yamamoto A., Deraison C., Bonnart C., Bitoun E., Robinson R., O'Brien T.J., Wakamatsu K., Ohtsubo S., Takahashi H., Hashimoto Y., Dopping-Hepenstal P.J., McGrath J.A., Iizuka H., Richard G., and Hovnanian A. LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum. J. Invest. Dermatol. 124 (2005) 360-366
71. Ishii K., Otsuka T., Iguchi K., Usui S., Yamamoto H., Sugimura Y., Yoshikawa K., Hayward S.W., and Hirano K. Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion. Cancer Lett. 207 (2004) 79-87
72. Kemper C., and Atkinson J.P. T-cell regulation: with complements from innate immunity. Nat. Rev. Immunol. 7 (2007) 9-18
73. Killian C.S., Corral D.A., Kawinski E., and Constantine R.I. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem. Biophys. Res. Commun. 192 (1993) 940-947
74. Kim J.W., Simmer J.P., Lin B.P., Seymen F., Bartlett J.D., and Hu J.C. Mutational analysis of candidate genes in 24 amelogenesis imperfecta families. Eur. J. Oral Sci. 114 Suppl. 1 (2006) 3-12
75. Kishi T., Grass L., Soosaipillai A., Scorilas A., Harbeck N., Schmalfeldt B., Dorn J., Mysliwiec M., Schmitt M., and Diamandis E.P. Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res. 63 (2003) 2771-2774
76. Kishi T., Cloutier S.M., Kundig C., Deperthes D., and Diamandis E.P. Activation and enzymatic characterization of recombinant human kallikrein 8. Biol. Chem. 387 (2006) 723-731
77. Kishibe M., Bando Y., Terayama R., Namikawa K., Takahashi H., Hashimoto Y., Ishida-Yamamoto A., Jiang Y.P., Mitrovic B., Perez D., Iizuka H., and Yoshida S. Kallikrein 8 is involved in skin desquamation in cooperation with other kallikreins. J. Biol. Chem. 282 (2006) 5834-5841
78. Koistinen H., Paju A., Koistinen R., Finne P., Lovgren J., Wu P., Seppala M., and Stenman U.H. Prostate-specific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP-3. Prostate 50 (2002) 112-118
79. Komatsu N., Takata M., Otsuki N., Ohka R., Amano O., Takehara K., and Saijoh K. Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides. J. Invest. Dermatol. 118 (2002) 436-443
80. Komatsu N., Saijoh K., Sidiropoulos M., Tsai B., Levesque M.A., Elliott M.B., Takehara K., and Diamandis E.P. Quantification of human tissue kallikreins in the stratum corneum: dependence on age and gender. J. Invest. Dermatol. 125 (2005) 1182-1189
81. Komatsu N., Saijoh K., Toyama T., Ohka R., Otsuki N., Hussack G., Takehara K., and Diamandis E.P. Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases. Br. J. Dermatol. 153 (2005) 274-281
82. Komatsu N., Suga Y., Saijoh K., Liu A.C., Khan S., Mizuno Y., Ikeda S., Wu H.K., Jayakumar A., Clayman G.L., Shirasaki F., Takehara K., and Diamandis E.P. Elevated human tissue kallikrein levels in the stratum corneum and serum of peeling skin syndrome-type B patients suggests an over-desquamation of corneocytes. J. Invest. Dermatol. 126 (2006) 2338-2342
83. Komatsu N., Saijoh K., Otsuki N., Kishi T., Micheal I.P., Obiezu C.V., Borgono C.A., Takehara K., Jayakumar A., Wu H.K., Clayman G.L., and Diamandis E.P. Proteolytic processing of human growth hormone by multiple tissue kallikreins and regulation by the serine protease inhibitor Kazal-Type5 (SPINK5) protein. Clin. Chim. Acta 377 (2007) 228-236
84. Kumar A., Goel A.S., Hill T.M., Mikolajczyk S.D., Millar L.S., Kuus-Reichel K., and Saedi M.S. Expression of human glandular kallikrein, hK2, in mammalian cells. Cancer Res. 56 (1996) 5397-5402
85. Kumar A., Mikolajczyk S.D., Goel A.S., Millar L.S., and Saedi M.S. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res. 57 (1997) 3111-3114
86. Kurlender L., Yousef G.M., Memari N., Robb J.D., Michael I.P., Borgono C., Katsaros D., Stephan C., Jung K., and Diamandis E.P. Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer. Tumour. Biol. 25 (2004) 149-156
87. Kyriakopoulou L.G., Yousef G.M., Scorilas A., Katsaros D., Massobrio M., Fracchioli S., and Diamandis E.P. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clin. Biochem 36 (2003) 135-143
88. Lai J., Kedda M.A., Hinze K., Smith R.L., Yaxley J., Spurdle A.B., Morris C.P., Harris J., and Clements J.A. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis 28 (2006) 1032-1039
89. Lauber T., Schulz A., Schweimer K., Adermann K., and Marx U.C. Homologous proteins with different folds: the three-dimensional structures of domains 1 and 6 of the multiple Kazal-type inhibitor LEKTI. J. Mol. Biol. 328 (2003) 205-219
90. Laxmikanthan G., Blaber S.I., Bernett M.J., Scarisbrick I.A., Juliano M.A., and Blaber M. 1.70 A X-ray structure of human apo kallikrein 1: structural changes upon peptide inhibitor/substrate binding. Proteins 58 (2005) 802-814
91. Li B., Goyal J., Dhar S., Dimri G., Evron E., Sukumar S., Wazer D.E., and Band V. CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. Cancer Res. 61 (2001) 8014-8021
92. Lovgren J., Rajakoski K., Karp M., Lundwall A., and Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem. Biophys. Res. Commun 238 (1997) 549-555
93. Lovgren J., Airas K., and Lilja H. Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors. Eur. J. Biochem. 262 (1999) 781-789
94. Lovgren J., Valtonen-Andre C., Marsal K., Lilja H., and Lundwall A. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids. J. Androl 20 (1999) 348-355
95. Lundwall A., Band V., Blaber M., Clements J.A., Courty Y., Diamandis E.P., Fritz H., Lilja H., Malm J., Maltais L.J., Olsson A.Y., Petraki C., Scorilas A., Sotiropoulou G., Stenman U.H., Stephan C., Talieri M., and Yousef G.M. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol. Chem. 387 (2006) 637-641
96. Lundwall A., Clauss A., and Olsson A.Y. Evolution of kallikrein-related peptidases in mammals and identification of a genetic locus encoding potential regulatory inhibitors. Biol. Chem. 387 (2006) 243-249
97. Luo L.Y., and Jiang W. Inhibition profiles of human tissue kallikreins by serine protease inhibitors. Biol. Chem. 387 (2006) 813-816
98. Luo L.Y., Katsaros D., Scorilas A., Fracchioli S., Bellino R., Van Gramberen M., De Bruijn H., Henrik A., Stenman U.H., Massobrio M., Van Der Zee A.G., Vergote I., and Diamandis E.P. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res. 63 (2003) 807-811
99. Luo L.Y., Shan S.J., Elliott M.B., Soosaipillai A., and Diamandis E.P. Purification and characterization of human kallikrein 11, a candidate prostate and ovarian cancer biomarker, from seminal plasma. Clin. Cancer Res. 12 (2006) 742-750
100. Magert H.J., Kreutzmann P., Standker L., Walden M., Drogemuller K., and Forssmann W.G. LEKTI: a multidomain serine proteinase inhibitor with pathophysiological relevance. Int. J. Biochem. Cell Biol. 34 (2002) 573-576
101. Magklara A., Brown T.J., and Diamandis E.P. Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. Int. J. Cancer 100 (2002) 507-514
102. Magklara A., Mellati A.A., Wasney G.A., Little S.P., Sotiropoulou G., Becker G.W., and Diamandis E.P. Characterization of the enzymatic activity of human kallikrein 6: autoactivation, substrate specificity, and regulation by inhibitors. Biochem. Biophys. Res. Commun. 307 (2003) 948-955
103. Malm J., Hellman J., Hogg P., and Lilja H. Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor. Prostate 45 (2000) 132-139
104. Matsumura M., Bhatt A.S., Andress D., Clegg N., Takayama T.K., Craik C.S., and Nelson P.S. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries. Prostate 62 (2005) 1-13
105. Memari N., Jiang W., Diamandis E.P., and Luo L.Y. Enzymatic properties of human kallikrein-related peptidase 12 (KLK12). Biol. Chem. 388 (2007) 427-435
106. Menashi S., Fridman R., Desrivieres S., Lu H., Legrand Y., and Soria C. Regulation of 92-kDa gelatinase B activity in the extracellular matrix by tissue kallikrein. Ann. N.Y. Acad. Sci. 732 (1994) 466-468
107. Michael I.P., Sotiropoulou G., Pampalakis G., Magklara A., Ghosh M., Wasney G., and Diamandis E.P. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J. Biol. Chem. 280 (2005) 14628-14635
108. Michael I.P., Pampalakis G., Mikolajczyk S.D., Malm J., Sotiropoulou G., and Diamandis E.P. Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression. J. Biol. Chem. 281 (2006) 12743-12750
109. Mikolajczyk S.D., Millar L.S., Kumar A., and Saedi M.S. Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1. Int. J. Cancer 81 (1999) 438-442
110. Moreau M.E., Garbacki N., Molinaro G., Brown N.J., Marceau F., and Adam A. The kallikrein-kinin system: current and future pharmacological targets. J. Pharmacol. Sci. 99 (2005) 6-38
111. Murtha P., Tindall D.J., and Young C.Y. Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5′ promoter region of the gene. Biochemistry 32 (1993) 6459-6464
112. Obiezu C.V., and Diamandis E.P. Human tissue kallikrein gene family: applications in cancer. Cancer Lett. 224 (2005) 1-22
113. Obiezu C.V., Michael I.P., Levesque M.A., and Diamandis E.P. Human kallikrein 4: enzymatic activity, inhibition, and degradation of extracellular matrix proteins. Biol. Chem. 387 (2006) 749-759
114. Oikonomopoulou K., Hansen K.K., Saifeddine M., Tea I., Blaber M., Blaber S.I., Scarisbrick I., Andrade-Gordon P., Cottrell G.S., Bunnett N.W., Diamandis E.P., and Hollenberg M.D. Proteinase-activated receptors, targets for kallikrein signaling. J. Biol. Chem. 281 (2006) 32095-32112
115. Paliouras M., and Diamandis E.P. Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines. Breast Cancer Res. Treat. 102 (2006) 7-19
116. Paliouras M., and Diamandis E.P. The kallikrein world: an update on the human tissue kallikreins. Biol. Chem. 387 (2006) 643-652
117. Paliouras M., Borgono C., and Diamandis E.P. Human tissue kallikreins: the cancer biomarker family. Cancer Lett. 249 (2007) 61-79
118. Pampalakis G., and Sotiropoulou G. Multiple mechanisms underlie the aberrant expression of the human kallikrein 6 gene in breast cancer. Biol. Chem. 387 (2006) 773-782
119. Peternac D., Klima I., Cecchini M.G., Studer U.E., and Thalmann G.N. Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth. J. Urol. 176 (2006) 354-360
120. Petraki C.D., Karavana V.N., Skoufogiannis P.T., Little S.P., Howarth D.J., Yousef G.M., and Diamandis E.P. The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. J. Histochem. Cytochem. 49 (2001) 1431-1441
121. Petraki C.D., Karavana V.N., Luo L.Y., and Diamandis E.P. Human kallikrein 10 expression in normal tissues by immunohistochemistry. J. Histochem. Cytochem. 50 (2002) 1247-1261
122. Petraki C.D., Karavana V.N., and Diamandis E.P. Human kallikrein 13 expression in normal tissues: an immunohistochemical study. J. Histochem. Cytochem. 51 (2003) 493-501
123. Picard D. Chaperoning steroid hormone action. Trends Endocrinol. Metab 17 (2006) 229-235
124. Pinkus G.S., Maier M., Seldin D.C., ole-MoiYoi O.K., Austen K.F., and Spragg J. Immunohistochemical localization of glandular kallikrein in the endocrine and exocrine human pancreas. J. Histochem. Cytochem. 31 (1983) 1279-1288
125. Prezas P., Scorilas A., Yfanti C., Viktorov P., Agnanti N., Diamandis E., and Talieri M. The role of human tissue kallikreins 7 and 8 in intracranial malignancies. Biol. Chem. 387 (2006) 1607-1612
126. Rajapakse S., Ogiwara K., Takano N., Moriyama A., and Takahashi T. Biochemical characterization of human kallikrein 8 and its possible involvement in the degradation of extracellular matrix proteins. FEBS Lett. 579 (2005) 6879-6884
127. Rawlings N.D., and Barrett A.J. Families of serine peptidases. Methods Enzymol. 244 (1994) 19-61
128. Rehault S., Monget P., Mazerbourg S., Tremblay R., Gutman N., Gauthier F., and Moreau T. Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur. J. Biochem. 268 (2001) 2960-2968
129. Rittenhouse H.G., Finlay J.A., Mikolajczyk S.D., and Partin A.W. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit. Rev. Clin. Lab Sci. 35 (1998) 275-368
130. Rochette-Egly C. Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell Signal. 15 (2003) 355-366
131. Romanov V.I., Whyard T., Adler H.L., Waltzer W.C., and Zucker S. Prostate cancer cell adhesion to bone marrow endothelium: the role of prostate-specific antigen. Cancer Res. 64 (2004) 2083-2089
132. Rosenfeld R.G. Insulin-like growth factors and the basis of growth. N. Engl. J. Med. 349 (2003) 2184-2186
133. Rousseau G.G. Control of gene expression by glucocorticoid hormones. Biochem. J. 224 (1984) 1-12
134. Samani A.A., Yakar S., Leroith D., and Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev. 28 (2006) 20-47
135. Saunders W.B., Bayless K.J., and Davis G.E. MMP-1 activation by serine proteases and MMP-10 induces human capillary tubular network collapse and regression in 3D collagen matrices. J. Cell Sci. 118 (2005) 2325-2340
136. Schechter N.M., Choi E.J., Wang Z.M., Hanakawa Y., Stanley J.R., Kang Y., Clayman G.L., and Jayakumar A. Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI). Biol. Chem. 386 (2005) 1173-1184
137. Schenone M., Furie B.C., and Furie B. The blood coagulation cascade. Curr. Opin. Hematol 11 (2004) 272-277
138. Schuur E.R., Henderson G.A., Kmetec L.A., Miller J.D., Lamparski H.G., and Henderson D.R. Prostate-specific antigen expression is regulated by an upstream enhancer. J. Biol. Chem. 271 (1996) 7043-7051
139. Scorilas A., Borgono C.A., Harbeck N., Dorn J., Schmalfeldt B., Schmitt M., and Diamandis E.P. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J. Clin. Oncol. 22 (2004) 678-685
140. Sharma J.N. Role of tissue kallikrein-kininogen-kinin pathways in the cardiovascular system. Arch. Med. Res. 37 (2006) 299-306
141. Shimizu C., Yoshida S., Shibata M., Kato K., Momota Y., Matsumoto K., Shiosaka T., Midorikawa R., Kamachi T., Kawabe A., and Shiosaka S. Characterization of recombinant and brain neuropsin, a plasticity-related serine protease. J. Biol. Chem. 273 (1998) 11189-11196
142. Sidenius N., and Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 22 (2003) 205-222
143. Sidera C., Parsons R., and Austen B. Proteolytic cascade in the amyloidogenesis of Alzheimer's disease. Biochem. Soc. Trans. 32 (2004) 33-36
144. Sidiropoulos M., Pampalakis G., Sotiropoulou G., Katsaros D., and Diamandis E.P. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumour. Biol. 26 (2005) 324-336
145. Silverman G.A., Bird P.I., Carrell R.W., Church F.C., Coughlin P.B., Gettins P.G., Irving J.A., Lomas D.A., Luke C.J., Moyer R.W., Pemberton P.A., Remold-O'Donnell E., Salvesen G.S., Travis J., and Whisstock J.C. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 276 (2001) 33293-33296
146. Simmer J.P., Fukae M., Tanabe T., Yamakoshi Y., Uchida T., Xue J., Margolis H.C., Shimizu M., DeHart B.C., Hu C.C., and Bartlett J.D. Purification, characterization, and cloning of enamel matrix serine proteinase 1. J. Dent. Res. 77 (1998) 377-386
147. Sohara Y., Shimada H., and DeClerck Y.A. Mechanisms of bone invasion and metastasis in human neuroblastoma. Cancer Lett. 228 (2005) 203-209
148. Sondell B., Thornell L.E., and Egelrud T. Evidence that stratum corneum chymotryptic enzyme is transported to the stratum corneum extracellular space via lamellar bodies. J. Invest. Dermatol. 104 (1995) 819-823
149. Sotiropoulou G., Rogakos V., Tsetsenis T., Pampalakis G., Zafiropoulos N., Simillides G., Yiotakis A., and Diamandis E.P. Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. Oncol. Res. 13 (2003) 381-391
150. Sprecher E., Chavanas S., DiGiovanna J.J., Amin S., Nielsen K., Prendiville J.S., Silverman R., Esterly N.B., Spraker M.K., Guelig E., de Luna M.L., Williams M.L., Buehler B., Siegfried E.C., Van Maldergem L., Pfendner E., Bale S.J., Uitto J., Hovnanian A., and Richard G. The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: implications for mutation detection and first case of prenatal diagnosis. J. Invest. Dermatol. 117 (2001) 179-187
151. Stefansson K., Brattsand M., Ny A., Glas B., and Egelrud T. Kallikrein-related peptidase 14 may be a major contributor to trypsin-like proteolytic activity in human stratum corneum. Biol. Chem. 387 (2006) 761-768
152. Stege R., Grande M., Carlstrom K., Tribukait B., and Pousette A. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin. Cancer Res. 6 (2000) 160-165
153. Stenman U.H., Leinonen J., Alfthan H., Rannikko S., Tuhkanen K., and Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 51 (1991) 222-226
154. Stephan C., Yousef G.M., Scorilas A., Jung K., Jung M., Kristiansen G., Hauptmann S., Bharaj B.S., Nakamura T., Loening S.A., and Diamandis E.P. Quantitative analysis of kallikrein 15 gene expression in prostate tissue. J. Urol. 169 (2003) 361-364
155. Stephanopoulos G., Garefalaki M.E., and Lyroudia K. Genes and related proteins involved in amelogenesis imperfecta. J. Dent. Res. 84 (2005) 1117-1126
156. Sun Z., Pan J., and Balk S.P. Androgen receptor-associated protein complex binds upstream of the androgen-responsive elements in the promoters of human prostate-specific antigen and kallikrein 2 genes. Nucleic Acids Res. 25 (1997) 3318-3325
157. Takayama T.K., McMullen B.A., Nelson P.S., Matsumura M., and Fujikawa K. Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 40 (2001) 15341-15348
158. Talieri M., Diamandis E.P., Gourgiotis D., Mathioudaki K., and Scorilas A. Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thromb. Haemost. 91 (2004) 180-186
159. Tamura H., Ishikawa Y., Hino N., Maeda M., Yoshida S., Kaku S., and Shiosaka S. Neuropsin is essential for early processes of memory acquisition and Schaffer collateral long-term potentiation in adult mouse hippocampus in vivo. J. Physiol. 570 (2006) 541-551
160. Tarttelin E.E., Bellingham J., Hankins M.W., Foster R.G., and Lucas R.J. Neuropsin (Opn5): a novel opsin identified in mammalian neural tissue. FEBS Lett. 554 (2003) 410-416
161. Terayama R., Bando Y., Takahashi T., and Yoshida S. Differential expression of neuropsin and protease M/neurosin in oligodendrocytes after injury to the spinal cord. Glia 48 (2004) 91-101
162. Thornberry N.A., Rano T.A., Peterson E.P., Rasper D.M., Timkey T., Garcia-Calvo M., Houtzager V.M., Nordstrom P.A., Roy S., Vaillancourt J.P., Chapman K.T., and Nicholson D.W. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem. 272 (1997) 17907-17911
163. Vaisanen V., Lovgren J., Hellman J., Piironen T., Lilja H., and Pettersson K. Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells. Prostate Cancer Prostatic. Dis. 2 (1999) 91-97
164. Veveris-Lowe T.L., Lawrence M.G., Collard R.L., Bui L., Herington A.C., Nicol D.L., and Clements J.A. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr. Relat Cancer 12 (2005) 631-643
165. Wang Y. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med. Res. Rev. 21 (2001) 146-170
166. Wang M.C., Valenzuela L.A., Murphy G.P., and Chu T.M. Purification of a human prostate specific antigen. Invest. Urol 17 (1979) 159-163
167. Wang C., Yeung F., Liu P.C., Attar R.M., Geng J., Chung L.W., Gottardis M., and Kao C. Identification of a novel transcription factor, GAGATA-binding protein, involved in androgen-mediated expression of prostate-specific antigen. J. Biol. Chem. 278 (2003) 32423-32430
168. Webber M.M., Waghray A., and Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin. Cancer Res. 1 (1995) 1089-1094
169. Wright J.T., Daly B., Simmons D., Hong S., Hart S.P., Hart T.C., Atsawasuwan P., and Yamauchi M. Human enamel phenotype associated with amelogenesis imperfecta and a kallikrein-4 (g.2142G > A) proteinase mutation. Eur. J. Oral Sci. 114 Suppl. 1 (2006) 13-17
170. Yakar S., Liu J.L., Stannard B., Butler A., Accili D., Sauer B., and Leroith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl. Acad. Sci. USA 96 (1999) 7324-7329
171. Yamakoshi Y., Hu J.C., Fukae M., Yamakoshi F., and Simmer J.P. How do enamelysin and kallikrein 4 process the 32-kDa enamelin?. Eur. J. Oral Sci. 114 Suppl. 1 (2006) 45-51
172. Yamasaki K., Schauber J., Coda A., Lin H., Dorschner R.A., Schechter N.M., Bonnart C., Descargues P., Hovnanian A., and Gallo R.L. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J. 20 (2006) 2068-2080
173. Yao Y.Y., Yin H., Shen B., Chao L., and Chao J. Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Regul. Pept. 140 (2006) 12-20
174. Yonou H., Aoyagi Y., Kanomata N., Kamijo T., Oda T., Yokose T., Hasebe T., Nagai K., Hatano T., Ogawa Y., and Ochiai A. Prostate-specific antigen induces osteoplastic changes by an autonomous mechanism. Biochem. Biophys. Res. Commun. 289 (2001) 1082-1087
175. Yousef G.M., and Diamandis E.P. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. 22 (2001) 184-204
176. Yousef G.M., and Diamandis E.P. Human tissue kallikreins: a new enzymatic cascade pathway?. Biol. Chem. 383 (2002) 1045-1057
177. Yousef G.M., Diamandis M., Jung K., and Diamandis E.P. Molecular cloning of a novel human acid phosphatase gene (ACPT) that is highly expressed in the testis. Genomics 74 (2001) 385-395
178. Yousef G.M., Kyriakopoulou L.G., Scorilas A., Fracchioli S., Ghiringhello B., Zarghooni M., Chang A., Diamandis M., Giardina G., Hartwick W.J., Richiardi G., Massobrio M., Diamandis E.P., and Katsaros D. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res. 61 (2001) 7811-7818
179. Yousef G.M., Kishi T., and Diamandis E.P. Role of kallikrein enzymes in the central nervous system. Clin. Chim. Acta 329 (2003) 1-8
180. Yousef G.M., Polymeris M.E., Grass L., Soosaipillai A., Chan P.C., Scorilas A., Borgono C., Harbeck N., Schmalfeldt B., Dorn J., Schmitt M., and Diamandis E.P. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res. 63 (2003) 3958-3965
181. Yousef G.M., Scorilas A., Nakamura T., Ellatif M.A., Ponzone R., Biglia N., Maggiorotto F., Roagna R., Sismondi P., and Diamandis E.P. The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. Breast Cancer Res. Treat. 78 (2003) 149-158
182. Yousef G.M., White N.M., Michael I.P., Cho J.C., Robb J.D., Kurlender L., Khan S., and Diamandis E.P. Identification of new splice variants and differential expression of the human kallikrein 10 gene, a candidate cancer biomarker. Tumour. Biol. 26 (2005) 227-235
183. Yu H., Levesque M.A., Clark G.M., and Diamandis E.P. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin. Cancer Res. 4 (1998) 1489-1497
184. Yu D.C., Sakamoto G.T., and Henderson D.R. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 59 (1999) 1498-1504
185. Zhao R., and Houry W.A. Hsp90: a chaperone for protein folding and gene regulation. Biochem. Cell Biol. 83 (2005) 703-710